Cerner Corporation and ICON Public Limited Company have announced an agreement that will provide pharmaceutical and device sponsors with late phase research technology to streamline the collection of information related to the safety, effectiveness and value of their medical products. As health care models continue to evolve, late phase research studies play a key role by providing additional assurance of product safety, comparative effectiveness, awareness of potential expanded indications for use and an understanding of the impact on patient outcomes and quality of life. ICON selected Cerner's Discovere(TM) Late Phase solution as its system of choice for its late phase projects after an extensive evaluation process.

Discovere Late Phase reduces the time required to start late phase studies, provides sites with an easy-to-use system for compiling data and expedites the reporting of valuable data back to sponsors and regulators. The solution can also integrate into the EHR workflow giving site researchers the ability to electronically transcribe study-relevant data from the EHR directly into the online study forms. Additionally, the system supports the capture of participant surveys and patient-reported outcomes through its integrated electronic patient-reported outcomes (ePRO) capabilities.